Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Orphan Drugs
  • R&D 100 Awards

Mammoth preparing to seek EUA for CRISPR COVID-19 test

By Tom Salemi | April 16, 2020

Mammoth BiosciencesCRISPR-startup Mammoth Biosciences will file for an emergency use application from the FDA after publishing a study in Nature Biotechnology that suggests its platform can detect SARS-CoV-2 from a respiratory swab RNA extracts in less than 45 minutes.

The company says the paper contains the first peer-reviewed data using CRISPR diagnostics for COVID-19.

In a release, Mammoth says its CRISPR tech offers faster, lower-cost alternatives to traditional quantitative polymerase chain reaction (qRT-PCR) tests. Those tests requires access to a specialized laboratory, typically requiring a 24-hour-plus turnaround, according to the company.

“We need faster, more accessible and scalable diagnostics,” said Janice Chen, chief technology officer of Mammoth, in a release. “The point-of-care testing space is ripe for disruption and CRISPR diagnostics have the potential to bring reliable testing to the most vulnerable environments.”

Chen said CRISPR can be programmed to detect any DNA or RNA sequence. The company reconfigured its DETECTR platform to detect the virus. The company collaborated Charles Chiu, MD, researchers from the Department of Laboratory Medicine at the University of California, San Francisco (UCSF), Dr. James Broughton, the research lead of the study.

The researchers validated the method using contrived reference samples and clinical samples from US patients, including 36 patients with COVID-19 infection and 42 patients with other viral respiratory infections.

Comments

  1. Phumlani Mkhize says

    April 20, 2020 at 2:21 am

    I think it is great. What are you guys waiting for? Go for the RNA Genome of the Virus. Use restriction endonuclease from the bacteria. Grow a bacteria in dish and introduce the Coronavirus in the Petri Dishes with bacteria. Or just introduce foreign ssRNA into a Petri Dishe with bacteria and see the bacteria can cut the ssRNA Genome of the Coronavirus. If the bacteria cuts the RNA GENOME of the Coronavirus the next step is to extract the enzyme from the bacteria and test the enzyme in the infected Human alveoli cell culture and see if you can repeat the same process of cutting the ssRNA Genome of the Coronavirus. If it does then we can start celebrating because you have find a way to kill the Virus. The challenging part is to find a bacteria that has the correct restriction endonuclease enzyme to cut.

    Thanks

    Phumlani Mkhize

    Reply

Tell Us What You Think! Cancel reply

Related Articles Read More >

AstraZeneca-Oxford
Study finds AstraZeneca COVID-19 vaccine could be effective against Brazil variant
RCSB Protein Data Bank now has more than 1,000 SARS-CoV-2 proteins
Data sciencea
Q&A: Keys to unlock data science potential for drug discovery
Ivermectin not supported for mild COVID-19, study says

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup

R&D Twitter

Tweets by @RandDWorld
Drug Discovery and Development
  • Enews Signup
  • Contact Us
  • R&D World
  • Pharmaceutical Processing
  • Drug Delivery Business News

Copyright © 2021 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Orphan Drugs
  • R&D 100 Awards